$XFOR News

Leerink Partners Initiates Coverage On X4 Pharmaceuticals with Outperform Rating, Announces Price Target of $12

X4 Pharmaceuticals Q1 EPS $(0.16) Beats $(0.20) Estimate, Sales $2.708M Miss $3.200M Estimate

X4 Pharma Says EC Grants Marketing Authorization For XOLREMDI Capsules For Treatment Of Patients With WHIM Syndrome In EU

X4 Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results.

X4 Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results.

X4 Pharmaceuticals Q4 EPS $(0.22) Beats $(0.38) Estimate, Sales $2.568M Beat $1.733M Estimate

X4 Pharmaceuticals shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and announced a $12 price target.

Guggenheim Initiates Coverage On X4 Pharmaceuticals with Buy Rating, Announces Price Target of $12

X4 Pharmaceuticals' Mavorixafor Secures Positive CHMP Opinion, Unlocking Up To €226M In Milestones Under Norgine Licensing Agreement

X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Tracking the Evolving Narrative for X4 Pharmaceuticals After Financing and Restructuring Moves

Stifel Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $10

Looking at the Narrative for X4 Pharmaceuticals After Leadership Changes and New Financing

WHIM Syndrome Research Analysis Report 2025-2035: Market Advances as X4 Pharmaceuticals Leads Innovation in CXCR4-Targeted Therapies

HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5

X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference

MeiraGTx Holdings PLC (MGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

X4 Pharmaceuticals: Q3 Earnings Snapshot

X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Q3 EPS $(0.69) Beats $(0.82) Estimate, Sales $1.765M Miss $1.901M Estimate